Table 3.
Outcomes and patient characteristics in pregnancies after IVF-FP cycles due to cancer
| Patient | Age at FP | Cancer diagnoses | Oocytes collected (n) | Type of oocyte maturation | Number of OO/ZYG cryopreserved | Time between FP and ET (months) | Embryos transferred (n) | Outcomes |
|---|---|---|---|---|---|---|---|---|
| 1 | 29 | Medullary hypoplasia | 9 | COS | 8 OO | 47 | 2 | Live birth |
| 2 | 29 | Breast | 7 | IVM | 6 OO | 65 | 1 | Live birth |
| 3 | 31 | Breast | 9 | IVM | 8 OO | 73 | 2 | Live birth |
| 4 | 36 | Breast | 9 | IVM | 4 ZYG | 64 | 2 | Live birth |
| 5 | 36 | Acute lymphoblastic leukemia | ||||||
| First ET | 27 | COS | 19 ZYG | 33 | 2 | Live birth | ||
| Second ET | 77 | 1 | Live birth | |||||
| 6 | 36 | Borderline tumor | 15 | COS | 6 ZYG | 14 | 2 | Live birth |
| 7 | 26 | Borderline tumor | 16 | COS | 7 ZYG | 12 | 2 | Live birth |
COS controlled ovarian stimulation, ET embryo transfer, IVM in vitro maturation, OO oocytes, FP fertility preservation, ZYG zygotes